| Name | Title | Contact Details |
|---|
Med MatRx is a Monaca, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Quigley Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Doylestown, PA. To find more information about The Quigley Corporation, please visit www.quigleyco.com
MPTF supports our entertainment community in living and aging well, with dignity and purpose, and in helping each other in times of need.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Founded in May 2020 by Dr. Kimon Angelides and publicly launched in October 2021, FemTec Health is the leading Health and Beauty Sciences Company focused on women`s health. Angelides has brought together a female-led team with decades of experience across healthcare, wellness, and consumer products in public and private companies. FemTec Health`s mission is to revolutionize women`s healthcare by using state-of-the-art genomics, predictive intelligence, and digital technologies to create an experience that is unified, coordinated, and provides personalized services and products that are meaningful and effective for women. With offices in Houston, New York, San Diego, London, Barcelona, Athens & Shanghai. FemTec Health currently has over 150 employees and is growing rapidly. Investors, capital and shareholders include Longmont Capital, Ltd and HellasMed, LLC (company principals), Walgreens, Trinity, Unilever Ventures.